The epidemiology of inhibitors in haemophilia A: a systematic review

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.

1994 • 352 citations

Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

1995 • 336 citations

Mortality and causes of death in Dutch haemophiliacs, 1973–86

1989 • 209 citations

Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates

1999 • 208 citations

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development

2001 • 202 citations

HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII

1997 • 195 citations

HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A

1997 • 194 citations

A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate

1993 • 189 citations

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A

1993 • 183 citations

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1993 • 179 citations

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1993 • 172 citations

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors

1988 • 171 citations

Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate

1997 • 168 citations

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII

1993 • 164 citations

Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.

1983 • 139 citations

Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France

1992 • 135 citations

A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.

1997 • 122 citations

A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A

1997 • 119 citations

Jaundice and Antibodies Directed against Factors VIII and IX in Patients Treated for Haemophilia or Christmas Disease in the United Kingdom

1974 • 111 citations

Acquired Circulating Anticoagulants in Hemophilia A

1969 • 108 citations

French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance

1998 • 90 citations

The natural history of factor VIII inhibitors in patients with hemophilia A.

1984 • 85 citations

Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates

1987 • 77 citations

Surveillance for Factor VIII Inhibitor Development in the Canadian Hemophilia A Population Following the Widespread Introduction of Recombinant Factor VIII Replacement Therapy

1998 • 77 citations

Treatment of Hemophilia A with a Highly Purified Factor VIII Concentrate Prepared by Anti-FVIIIc Immunoaffinity Chromatography

1992 • 72 citations

Incidence of Factor VIII Inhibitor Development in Hemophilia A Patients Treated with Less Pure Plasma Derived Concentrates

1994 • 69 citations

Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome

1990 • 66 citations

Comparative analysis of Y chromosome structure in Bos taurus and <i>B. indicu</i><i>s</i> by FISH using region-specific, microdissected, and locus-specific DNA probes

1997 • 62 citations

Absence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A after Exposure to a Single Intermediate Purity Factor VIII Product

1997 • 62 citations

Treatment of haemophilia in the United Kingdom 1981-1996

2001 • 59 citations

Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.

1990 • 54 citations

Development of inhibitors in patients with haemophilia from India

2001 • 54 citations

A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.

1997 • 54 citations

A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A

1997 • 47 citations

Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate

1993 • 47 citations

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

1999 • 44 citations

Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate

1995 • 44 citations

Treatment of haemophilia in the United Kingdom 1981–1996

2001 • 37 citations

The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93

1995 • 32 citations

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C

1991 • 27 citations

Incidence and Course of Inhibitors among Patients with Classic Hemophilia

1973 • 26 citations

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A

2001 • 24 citations

Haemophilia Complicated by an Acquired Circulating Anti‐Coagulant: A Report of Three Cases

1961 • 23 citations

The history of synoviorthesis in haemophilia

2001 • 22 citations

Online searching: Principles and practice.

1991 • 19 citations

Analysis of a Large Collection of Natural HIV-1 Integrase Sequences, Including Those From Long-Term Nonprogressors

1998 • 18 citations

Factor VIII Inhibitors in Patients with Hemophilia A

1999 • 17 citations

Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates

1999 • 16 citations

Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low‐dose immune tolerance induction

2000 • 16 citations

Factor VIII Inhibitors and the Use of Blood Products in Patients with Haemophilia A

1971 • 16 citations

Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.

1990 • 9 citations

Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.

1993 • 9 citations

Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A

2001 • 9 citations

Clinical patterns of hemophilic patients who develop inhibitors.

1984 • 7 citations

Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities

1995 • 4 citations

Zero incidence of inhibitor development in previously treated Haemophilia A, HIV‐negative patients upon exposure to a plasma‐derived high‐purity and double viral inactivated factor VIII concentrate

1998 • 3 citations

[Incidence of inhibitors in children with hemophilia A].

1988 • 2 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...